This excerpt taken from the IMX DEF 14A filed Nov 15, 2005.
Certain Relationships and Related Transactions
Our CEO and Chairman of the Board of Directors is also a director of CardioTech. The CEO and Chairman of the Board of Directors of CardioTech is also our director.
In March 2000, the Company entered into a joint research agreement with CardioTech to develop a proprietary porous polymer biocompatible coating technology as a platform for the Companys proprietary radioactive brachytherapy technology. In consideration for this agreement, the Company agreed to pay $150,000 in cash and purchase 100,000 shares of CardioTech stock at a price of $1.00 per share. As of June 30, 2005, the Company has purchased these shares, the fair market value of which is $179,000 and is recorded as investments in available for sale securities in the accompanying consolidated balance sheet.
In March 2004 the Company entered into an Exchange & Venture Agreement with CardioTech International, Inc. (CardioTech), a public company and related party of the Company, and CorNova, Inc. (CorNova). CorNova is a start-up company incorporated as a Delaware corporation on October 12, 2003. CorNovas focus is the development and marketing of innovative interventional cardiology products. In connection with the agreement, in March 2004, the Company and CardioTech issued 10,344 and 12,931 shares, respectively, of their respective common stock (the Contributory Shares) bearing an aggregate fair market value of $113,000 and $76,000, respectively, as of the date of the issuance. In exchange, the Company and CardioTech each received 1,500,000 shares of CorNovas common stock, which represented a 30% ownership position for each party. In February 2005, upon CorNovas securing of an additional $3,000,000 in financing (Series A), CardioTech and the Company each issued additional shares of their common stock, which was equal in value to twenty-five percent (25%) of the gross proceeds of the Series A Financing, or $750,000. As of June 30, 2005, the Companys shares, represent a 19% ownership position. Anthony Armini, our CEO and Michael Szycher, the Chairman of our Nominating Committee, are also on the Board of Directors of CorNova.